Vaccine maker Sinovac H1 revenue rises on overseas growth, approvals - SVA News | RalliesVaccine maker Sinovac H1 revenue rises on overseas growth, approvals
S
SVA• Outlook
- Company expects commercialization of innovative products to drive domestic growth going forward
- Sinovac plans to submit NDA for PCV13 vaccine in Q3 2026
- Company aims to broaden global access to its rabies vaccine through WHO prequalification
Overview
- China vaccine maker's unaudited H1 revenue rose 13% yr/yr, led by overseas sales growth
- Net loss attributable to common shareholders widened despite higher gross margin
- Company cites overseas demand and international approvals as key revenue drivers
Key details
| Metric | Actual |
|---|
| H1 Revenue | $147.08 mln |
| H1 Loss Per Share | $0.84 |
| H1 Net Loss | $91.40 mln |
| H1 Gross Profit | $95.54 mln |
| H1 Loss Per Basic Share | $0.84 |
| H1 Operating Expenses | $213.58 mln |
| H1 Operating Income | -$118.04 mln |
| H1 Pretax Loss | $69.84 mln |
Result Drivers
- Overseas sales - Revenue growth was primarily driven by an 82% increase in overseas sales, which accounted for 45% of total revenue
•
